Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Patients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management because of multiple potential mechanisms and the unclear tolerability of drug combinations. A pa...
Alternative Titles
Full title
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2cb1c36a9a5542459cc53204816c9e28
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2cb1c36a9a5542459cc53204816c9e28
Other Identifiers
ISSN
2397-768X
E-ISSN
2397-768X
DOI
10.1038/s41698-024-00563-4
